Revolution Medicines, Inc. (RVMD) has a negative trailing P/E of -16.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 28.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -6.15%, forward earnings yield 3.55%.
Criteria proven by this page:
Overall SharesGrow Score: 43/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -33.9 | 0.00 | 232.64 | 0.00 | - |
| 2018 | -25.2 | -0.71 | 10.91 | 52.27 | - |
| 2019 | -22.1 | -1.59 | 6.91 | 21.06 | - |
| 2020 | -24.4 | -1.03 | 5.55 | 61.34 | - |
| 2021 | -9.8 | -0.19 | 3.04 | 62.35 | - |
| 2022 | -7.7 | -0.31 | 2.80 | 54.28 | - |
| 2023 | -7.4 | -0.29 | 1.78 | 280.24 | - |
| 2024 | -12.2 | 1.69 | 3.24 | 0.00 | - |
| 2025 | -13.4 | -0.20 | 9.28 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.85 | $0.00 | $-31.13M | - |
| 2018 | $-1.15 | $20.17M | $-41.79M | -207.2% |
| 2019 | $-0.81 | $50.04M | $-47.66M | -95.2% |
| 2020 | $-1.62 | $42.98M | $-108.16M | -251.6% |
| 2021 | $-2.47 | $29.39M | $-179.77M | -611.7% |
| 2022 | $-3.08 | $35.38M | $-248.71M | -703% |
| 2023 | $-3.86 | $11.58M | $-436.37M | -3768.3% |
| 2024 | $-3.58 | $0.00 | $-600.09M | - |
| 2025 | $-5.95 | $0.00 | $-1.13B | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-7.74 | $-8.58 – $-6.08 | $54.39M | $7.47M – $136.9M | 17 |
| 2027 | $-6.77 | $-8.46 – $-3.36 | $374.28M | $46.89M – $932.64M | 14 |
| 2028 | $-4.61 | $-8.36 – $0.70 | $981.34M | $968.56M – $994.12M | 12 |
| 2029 | $-0.43 | $-1.30 – $0.06 | $2.09B | $268.42M – $5.3B | 10 |
| 2030 | $5.22 | $-0.69 – $15.64 | $3.68B | $472.56M – $9.33B | 5 |
